ArticleScientific reports2026
Diagnostic performance of stimulated plasma interferon-gamma inducible protein 10 (IP-10) for diagnosing latent tuberculosis infection in healthcare workers.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the absence of a definitive gold standard for diagnosing latent tuberculosis infection (LTBI) in healthcare workers (HCWs), alternative specific biomarkers are needed. This longitudinal cohort study with baseline testing evaluated the diagnostic performance of stimulated plasma interferon-γ inducible protein 10 (IP-10) for LTBI detection among HCWs in a high tuberculosis (TB)-burden setting, using interferon-γ release assays (IGRAs) as the reference standard. The study was conducted at Songklanagarind Hospital, Thailand, between 2021 and 2024, and included 64 healthy HCWs. Serum and stimulated plasma samples were collected, and IP-10 and IFN-γ concentrations were measured by ELISA. Nine HCWs (14.0%) were LTBI-positive. Stimulated plasma IP-10, but not serum IP-10, showed significant correlations with IFN-γ levels in TB1 (r = 0.719) and TB2 (r = 0.768; p < 0.0001) tubes. At cut-off values of ≥ 2,980.0 pg/mL for TB1 and ≥ 3,108.0 pg/mL for TB2, sensitivity was 100%, specificity was 96.0% and 94.5%, and overall accuracy was 96.8% and 95.3%, respectively. Based on either IGRA or stimulated plasma IP-10 cut-off levels, five of nine LTBI cases declined treatment; among these, one individual (20.0%) progressed to active pulmonary TB 16 months later. Stimulated plasma IP-10 shows high diagnostic performance for LTBI detection among HCWs and may serve as an alternative for LTBI screening in high-TB-incidence with universal BCG vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.